Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 12:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Photopheresis Clear all
Recruiting Phase 2 Interventional

Photopheresis in Early-stage Mycosis Fungoides

NCT05680558
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 7, 2026, 12:42 AM EDT
Completed Phase 2 Interventional Results available

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

NCT00639717
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 7, 2026, 12:42 AM EDT
Not listed Phase 1 Interventional

Safety Study of the HemoModulator System for the Treatment of Patients With Human Immunodeficiency Virus (HIV)

NCT00858923
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Energex HemoModulator
Device
Lead sponsor
Energex Systems, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Sep 7, 2026, 12:42 AM EDT
Withdrawn Phase 2 Interventional

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

NCT05333029
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP)
Biological
Lead sponsor
Molly Gallogly
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 7, 2026, 12:42 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
INCA034176, Best available Treatment (BAT)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 7, 2026, 12:42 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis

NCT00221000
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methoxsalen, Extracorporeal Photopheresis
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
10
States / cities
Westminister, Maryland • Worchester, Massachusetts • Morristown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 7, 2026, 12:42 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease

NCT00221026
View directory record Official record
Conditions
Crohn's Disease
Interventions
Methoxsalen +ECP, Extracorporeal Photopheresis
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Bethesda, Maryland • Chevy Chase, Maryland • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 7, 2026, 12:42 AM EDT
Withdrawn Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD

NCT02694770
View directory record Official record
Conditions
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
Interventions
Neihulizumab Treatment, Conventional Treatment
Biological
Lead sponsor
AbGenomics B.V Taiwan Branch
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 24, 2016 · Synced Sep 7, 2026, 12:42 AM EDT
Recruiting Phase 2 Interventional

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

NCT04930653
View directory record Official record
Conditions
Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Transformed Mycosis Fungoides
Interventions
Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 7, 2026, 12:42 AM EDT
Terminated Phase 2 Interventional Results available

Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD

NCT04446182
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Itacitinib, Extracorporeal Photopheresis (ECP)
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Sep 7, 2026, 12:42 AM EDT
Completed Early Phase 1 Interventional Results available

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

NCT01380535
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
ECP Methoxsalen, Standard of Care
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Miami, Florida • Indianapolis, Indiana • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 7, 2026, 12:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 7, 2026, 12:42 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Umbilical Cord Blood Transplantation

NCT00676806
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Aplastic Anemia
Interventions
Umbilical Cord Blood After Myeloablative Conditioning, Umbilical Cord Blood After Reduced-Intensity Conditioning
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
Up to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 7, 2026, 12:42 AM EDT
Completed Not applicable Interventional Results available

A Randomized Trial Examining Plasma Exchange Using the Becton Dickinson (BD) Catheter In an Outpatient Apheresis Unit

NCT04253756
View directory record Official record
Conditions
Plasma Exchange
Interventions
20-gauge BD Nexiva Diffusics
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 7, 2026, 12:42 AM EDT
Active, not recruiting Phase 3 Interventional

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

NCT02181257
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Interventions
Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
Combination Product · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 7, 2026, 12:42 AM EDT
Completed Phase 4 Interventional

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

NCT00221039
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions
Methoxsalen+ECP
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 7, 2026, 12:42 AM EDT
Completed Phase 1Phase 2 Interventional

Reduced Intensity Transplant Using Extracorporeal Photopheresis

NCT00179790
View directory record Official record
Conditions
Leukemia, Cancer
Interventions
Extracorporeal Photopheresis
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 7, 2026, 12:42 AM EDT
Terminated Phase 2 Interventional Results available

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

NCT02322190
View directory record Official record
Conditions
Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
Extracorporeal Photopheresis (ECP), Methoxsalen
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 7, 2026, 12:42 AM EDT
Completed Phase 1 Interventional

Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease

NCT00056355
View directory record Official record
Conditions
Crohn Disease
Interventions
UVADEX and UVAR XTS Photopheresis System
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 7, 2026, 12:42 AM EDT
Terminated Phase 1Phase 2 Interventional

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

NCT04676087
View directory record Official record
Conditions
Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
Interventions
Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment
Procedure · Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 7, 2026, 12:42 AM EDT
Completed No phase listed Observational

Immuno-regulatory Profiling of T Cells in GVHD Treated With Extracorporeal Photopheresis

NCT03851601
View directory record Official record
Conditions
GVHD
Interventions
blood samples
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 7, 2026, 12:42 AM EDT
Terminated Not applicable Interventional Results available

Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis

NCT02296346
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
SoluMedrol, Extracorporeal Photopheresis
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 7, 2026, 12:42 AM EDT
Completed Phase 2Phase 3 Interventional

Extracorporeal Photopheresis for Acute Graft Versus Host Disease

NCT00179855
View directory record Official record
Conditions
Graft Versus Host Disease, Cancer, Stem Cell Transplantation
Interventions
Extracorporeal Photopheresis
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 7, 2026, 12:42 AM EDT
Recruiting Phase 2 Interventional

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

NCT06663722
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, cGVHD
Interventions
Axatilimab, Extracorporeal Photopheresis
Biological · Procedure
Lead sponsor
University of Miami
Other
Eligibility
12 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 7, 2026, 12:42 AM EDT